BioTech
GSK

GSK's long-acting HIV injection endorsed by EU panel

Credit: REUTERS/MATTHEW CHILDS

GlaxoSmithKline Plc said on Friday an injection of its cabotegravir drug given every two months along with Johnson & Johnson's rilpivirine was recommended for approval to treat HIV infections by a panel of the European health regulator.

Oct 16 (Reuters) - GlaxoSmithKline Plc GSK.L said on Friday an injection of its cabotegravir drug given every two months along with Johnson & Johnson's JNJ.N rilpivirine was recommended for approval to treat HIV infections by a panel of the European health regulator.

The treatment is a long-acting regimen, which can reduce the number of doses required to 12 or six per year instead of a daily intake of pills.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Ramakrishnan M.)

((Aakash.B@thomsonreuters.com; Twitter: @JagadeeshAakash;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GSK JNJ

Other Topics

US Markets

Latest Technology Videos

    The Robo Advisor vs. Human Element of Investing

    Investopedia Editor-in-Chief Caleb Silver discusses the Robo Advisor vs. Human element of investing. #NationalFinancialPlanning

    3 days ago

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More